Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability

Drug Development and Industrial Pharmacy

Volumn 37, Issue 1, 2011, Pages 15-23

  Wu, Xuemei ^a   Xu, Jianhua ^a   Huang, Xiuwang ^a   Wen, Caixia ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Curcumin; Dissolution; SMEDDS; Stability

Indexed keywords

ALCOHOL; COSURFACTANT; CREMOPHOR; CURCUMIN; MYRISTIC ACID ISOPROPYL ESTER; OIL; SURFACTANT;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; MALE; MICROEMULSION; MOUSE; NONHUMAN; PARTICLE SIZE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; EMULSIONS; MALE; MICE; OILS; PARTICLE SIZE; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 78650024236     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.489560     Document Type: Article

References (46)

1. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. (1995). Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett, 94:79-83.
2. Srimal RC, Dhawan BN. (1973). Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inammatory agent. J Pharm Pharmacol, 25:447-52.
3. Sugiyama Y, Kawakishi S, Osawa T. (1996). Involvement of the β-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol, 52:519-25.
4. Kim MK, Choi GJ, Lee HS. (2003). Fungicidal property of Curcuma longa L. rhizome-derived curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem, 51:1578-81.
5. Mahady GB, Pendland SL, Yun G, Lu ZZ. (2002). Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res, 22:4179-81.
6. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. (2005). Curcumin for malaria therapy. Biochem Biophys Res Commun, 326:472-4.
7. Qureshi S, Shah AH, Ageel AM. (1992). Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med, 58:124-7.
8. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. (1980). Toxicity studies on turmeric (Curcuma longa): Acute toxicity studies in rats, guineapigs & monkeys. Indian J Exp Biol, 18:73-5.
9. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res, 21(4B):2895-900.
10. Lao CD, Demierre MF, Sondak VK. (2006). Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther, 6:1559-68.
11. Lao CD, Rufn MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. (2006). Dose escalation of a curcuminoid formulation. BMC Complement Altern Med, 6:10-7.
12. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. (2007). Curcumin: The Indian solid gold. Adv Exp Med Biol, 595:1-75.
13. Anant P, Anshuman AA, Bhimrao KJ, Mahadik KR. (2004). Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm, 271:281-6.
14. Ansari MJ, Ahmad S, Kohli K, Ali J, Khar RK. (2005). Stabilityindicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. J Pharm Biomed Anal, 39:132-8.
15. Ravindranath V, Chandrasekhara N. (1980). Absorption and tissue distribution of curcumin in rats. Toxicology, 16:259-65.
16. Cui SM, Zhao CS, Chen DW, He ZG. (2005). Self-microemulsifying drug delivery systems (SMEDDS) for improving in vitro dissolution and oral absorption of Pueraria lobata isoflavone. Drug Dev Ind Pharm, 31:349-56.
17. Attivi D, Ajana I, Astier A, Demoré B, Gibaud S. (2010). Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm, 36:421-7.
18. Patel D, Sawant KK. (2007). Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm, 33:1318-26.
19. Wei L, Sun P, Nie S, Pan W. (2005). Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm, 31:785-94.
20. Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89-121.
21. Paul BK, Moulik SP. (1997). Microemulsions: An overview. J Dispers Sci Technol, 8:301-67.
22. Teichmann A, Heuschkel S, Jacobi U, Presse G, Neubert RH, Sterry W, et al. (2007). Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm, 67:699-706.
23. Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H, et al. (2009). Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm, 371:148-55.
24. Xu HL, Sun Y, Shao JZ, Xiong LR, Zhang N, Huang CG. (2007). Study on pharmacokinetics of the curcumin liposomes in rat. J Hubei Coll Tradit Chin Med, 9:42-5.
25. Chen Y, Li G, Wu XG, Chen ZY, Hang JG, Qin B, et al. (2008). Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: Formulation development and in vivo assessment. Biol Pharm Bull, 31:118-25.
26. Pharmacopoeia of the People's Republic of China. II [S]. (2005). Appendix 73.
27. Pouton CW. (1985). Self-emulsifying drug delivery systems: Assessment of the efficiency of emulsification. Int J Pharm, 27:335-48.
28. Borhade VB, Nair HA, Hegde DD. (2009). Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration. Drug Dev Ind Pharm, 35:619-30.
29. Constantinides PP. (1995). Lipid microemulsion for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res, 12:1561-72.
30. Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JP. (2009). Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm, 35:603-11.
31. Meng J, Zheng LY. (2007). Application of mixture experimental design to simvastatin apparent solubility predictions in the microemulsifion formed by self-microemulsifying. Drug Dev Ind Pharm, 33:927-31.
32. Eccleston GM. (1992). Microemulsions. In: Swarbrick S, Boylan JC, eds. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker, Inc., 375-421.
33. Pouton CW. (1985). Effects of inclusion of a model drug on the performance of self-emulsifying formulations. J Pharm Pharmacol, 37:1-11.
34. Gershanik T, Benita S. (2000). Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm, 50:179-88.
35. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, et al. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274:65-73.
36. O'Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15:405-15.
37. Yuan Q, Li XR, Wang HJ, Li XY, Liu Y. (2004). The absorption kinetics of silymarin microemulsion in rat intestine. Acta Pharmacol Sin, 39:631-4.
38. Swenson ES, Milisen WB, Curatolo W. (1994). Intestinal permeability enhancement: Efficacy, acute local toxicity and reversibility. Pharm Res, 11:1132-42.
39. Gursoy RN, Benita S. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 58:173-82.
40. Wahlstrom B, Blennow G. (1978). A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh), 43:86-92.
41. Pan MH, Huang TM, Lin JK. (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos, 27:486-94.
42. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med, 64:353-6.
43. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. (1994). Self-emulsifying drug delivery system (SEDDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm, 106:15-23.
44. Sha XY, Yan GJ, Wu YJ, Li JC, Fang XL. (2005). Effect of self-microemulsifying drug delivery systems containing labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci, 24:477-86.
45. Trevaskis NL, Charman WN, Porter CJ. (2008). Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev, 60:702-16.
46. Woo JS, Lee CH, Shim CK, Hwang SC. (2003). Enhanced oral bioavailability of paclitaxel by co-administration of the P-glycoprotein inhibitor KR30031. Pharm Res, 20:24-30.